eduKateSG · Why Science?
Show that a new dosage form remains fit for patients by connecting its approved active ingredient knowledge to fresh formulation, package and stability evidence
Read FDA’s final May 1997 ICH Q1C guidance through new dosage forms, Q1A principles, comparative knowledge, formulation and package differences, representative batches, attributes, shelf life and the separate June 2025 consolidated Q1 draft.
A medicine can contain a familiar active ingredient and still behave differently when scientists turn a tablet into a liquid, change an immediate-release product into a modified-release form or create another presentation for a new patient need.
FDA lists ICH Q1C as final guidance dated May 1997. It says stability protocols for new dosage forms should follow the principles of the parent Q1A guidance, while recognising that justified reduced data can sometimes be acceptable at submission.
Did you know? “Same active ingredient” does not mean “same stability.” Water activity, excipients, manufacturing steps, dose delivery and package protection can create new degradation or physical-change pathways.
FDA also published a consolidated ICH Q1 draft in June 2025. That draft is not for implementation. This article distinguishes its future-facing revision from the current final Q1C page.
Chapter index
Chapters 1–9: May 1997 final Q1C and new dosage forms
- 1. Q1C addresses a new dosage form for an approved drug substance
- 2. FDA lists Q1C as final guidance from May 1997
- 3. The June 2025 consolidated Q1 document has draft status
- 4. Prior knowledge can inform but cannot substitute for new-form evidence
- 5. The dosage-form change defines the scientific questions
- 6. Route of administration can change critical attributes
- 7. Excipients can create new chemical and physical interactions
- 8. Manufacturing history affects the starting state
- 9. The proposed package belongs to the dosage form
Chapters 10–17: Q1A principles, formulation, package, route, strength, stability attributes and lifecycle evidence
- 10. Q1A-style long-term and accelerated studies remain the foundation
- 11. Attributes follow the new product’s quality risks
- 12. Stability-indicating methods must work in the new matrix
- 13. Comparative data can make the bridge transparent
- 14. Reduced submission data require justification and commitments
- 15. In-use stability may matter after opening or preparation
- 16. Lifecycle changes can reopen the stability bridge
- 17. A complete Q1C receipt explains why the new form remains suitable
CHAPTER 1 OF 17 · Define the new form
1. Q1C addresses a new dosage form for an approved drug substance
The guidance concerns a product that contains the same active substance as an approved product but differs in dosage form. Examples can include a different route or delivery design. The new form needs evidence for its own formulation, manufacture, container closure and use.
The scientific value of q1c addresses a new dosage form for an approved drug substance appears when evidence is tied to a defined regulatory decision. The guidance concerns a product that contains the same active substance as an approved product but differs in dosage form. Examples can include a different route or delivery design. The new form needs evidence for its own formulation, manufacture, container closure and use. Keep this boundary visible: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
Try this
Build an evidence map for q1c addresses a new dosage form for an approved drug substance. Compare q1c addresses a new dosage form for an approved drug substance with the approved product and list every new uncertainty. Add the decision, owner and acceptance criterion. Keep this limit: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
A strong science note separates observation from interpretation. Compare q1c addresses a new dosage form for an approved drug substance with the approved product and list every new uncertainty. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Compare q1c addresses a new dosage form for an approved drug substance with the approved product and list every new uncertainty. Keep this boundary visible: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
CHAPTER 2 OF 17 · Define the new form
2. FDA lists Q1C as final guidance from May 1997
The official FDA page identifies Q1C as final and names CDER and CBER. The document is concise because it relies on the parent stability framework rather than repeating every Q1A principle.
For fda lists q1c as final guidance from may 1997, a useful explanation shows the material, method, result and decision together. The official FDA page identifies Q1C as final and names CDER and CBER. The document is concise because it relies on the parent stability framework rather than repeating every Q1A principle. Preserve this guardrail: A new route or delivery system can create patient-relevant attributes absent from the original dosage form.
Try this
Challenge the assumptions behind fda lists q1c as final guidance from may 1997. Stress the formulation and package assumptions behind fda lists q1c as final guidance from may 1997. Test a plausible failure mode and record the result. Respect this boundary: A new route or delivery system can create patient-relevant attributes absent from the original dosage form.
A strong science note separates observation from interpretation. Stress the formulation and package assumptions behind fda lists q1c as final guidance from may 1997. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Stress the formulation and package assumptions behind fda lists q1c as final guidance from may 1997. Keep this boundary visible: A new route or delivery system can create patient-relevant attributes absent from the original dosage form.
CHAPTER 3 OF 17 · Define the new form
3. The June 2025 consolidated Q1 document has draft status
FDA describes the June 2025 Q1 draft as a consolidated revision of Q1A(R2), Q1B, Q1C, Q1D, Q1E and Q5C. It is not for implementation. A current article should not imply that the draft has replaced final Q1C.
A trustworthy account of the june 2025 consolidated q1 document has draft status keeps assumptions, uncertainty and lifecycle action in the same record. FDA describes the June 2025 Q1 draft as a consolidated revision of Q1A(R2), Q1B, Q1C, Q1D, Q1E and Q5C. It is not for implementation. A current article should not imply that the draft has replaced final Q1C. Remember: Reduced data at submission do not mean reduced responsibility for ongoing real-time studies.
Try this
Audit the lifecycle record for the june 2025 consolidated q1 document has draft status. Trace the june 2025 consolidated q1 document has draft status through manufacture, storage, opening and patient use. Mark what changed, why it changed and what evidence closed the question. Preserve this caution: Reduced data at submission do not mean reduced responsibility for ongoing real-time studies.
A strong science note separates observation from interpretation. Trace the june 2025 consolidated q1 document has draft status through manufacture, storage, opening and patient use. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace the june 2025 consolidated q1 document has draft status through manufacture, storage, opening and patient use. Keep this boundary visible: Reduced data at submission do not mean reduced responsibility for ongoing real-time studies.
CHAPTER 4 OF 17 · Define the new form
4. Prior knowledge can inform but cannot substitute for new-form evidence
Knowledge of the active ingredient, degradation pathways and approved product helps design the programme. It can identify likely risks and methods. It does not prove that a new matrix, process or package will protect the product in the same way.
The scientific value of prior knowledge can inform but cannot substitute for new-form evidence appears when evidence is tied to a defined regulatory decision. Knowledge of the active ingredient, degradation pathways and approved product helps design the programme. It can identify likely risks and methods. It does not prove that a new matrix, process or package will protect the product in the same way. Keep this boundary visible: The June 2025 consolidated Q1 document remains a draft, not for implementation.
Try this
Build an evidence map for prior knowledge can inform but cannot substitute for new-form evidence. Reassess prior knowledge can inform but cannot substitute for new-form evidence after a formulation, site, process, strength or package change. Add the decision, owner and acceptance criterion. Keep this limit: The June 2025 consolidated Q1 document remains a draft, not for implementation.
A strong science note separates observation from interpretation. Reassess prior knowledge can inform but cannot substitute for new-form evidence after a formulation, site, process, strength or package change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reassess prior knowledge can inform but cannot substitute for new-form evidence after a formulation, site, process, strength or package change. Keep this boundary visible: The June 2025 consolidated Q1 document remains a draft, not for implementation.
CHAPTER 5 OF 17 · Carry knowledge forward
5. The dosage-form change defines the scientific questions
A solution may introduce hydrolysis; a suspension may settle or change particle size; a transdermal system may lose adhesion; a modified-release tablet may change dissolution. The protocol begins with what the new form can do differently.
For the dosage-form change defines the scientific questions, a useful explanation shows the material, method, result and decision together. A solution may introduce hydrolysis; a suspension may settle or change particle size; a transdermal system may lose adhesion; a modified-release tablet may change dissolution. The protocol begins with what the new form can do differently. Preserve this guardrail: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
Try this
Challenge the assumptions behind the dosage-form change defines the scientific questions. Compare the dosage-form change defines the scientific questions with the approved product and list every new uncertainty. Test a plausible failure mode and record the result. Respect this boundary: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
A strong science note separates observation from interpretation. Compare the dosage-form change defines the scientific questions with the approved product and list every new uncertainty. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Compare the dosage-form change defines the scientific questions with the approved product and list every new uncertainty. Keep this boundary visible: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
CHAPTER 6 OF 17 · Carry knowledge forward
6. Route of administration can change critical attributes
Oral, injectable, topical, inhaled and other routes expose patients to different risks. Sterility, particulate matter, dose uniformity, delivery performance, preservative effectiveness or device function may become stability attributes when relevant.
A trustworthy account of route of administration can change critical attributes keeps assumptions, uncertainty and lifecycle action in the same record. Oral, injectable, topical, inhaled and other routes expose patients to different risks. Sterility, particulate matter, dose uniformity, delivery performance, preservative effectiveness or device function may become stability attributes when relevant. Remember: A new route or delivery system can create patient-relevant attributes absent from the original dosage form.
Try this
Audit the lifecycle record for route of administration can change critical attributes. Stress the formulation and package assumptions behind route of administration can change critical attributes. Mark what changed, why it changed and what evidence closed the question. Preserve this caution: A new route or delivery system can create patient-relevant attributes absent from the original dosage form.
A strong science note separates observation from interpretation. Stress the formulation and package assumptions behind route of administration can change critical attributes. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Stress the formulation and package assumptions behind route of administration can change critical attributes. Keep this boundary visible: A new route or delivery system can create patient-relevant attributes absent from the original dosage form.
CHAPTER 7 OF 17 · Carry knowledge forward
7. Excipients can create new chemical and physical interactions
Buffers, surfactants, preservatives, polymers, colours and flavours can change pH, moisture, oxygen exposure, solubility or degradation. Compatibility and stress studies help distinguish active-ingredient pathways from formulation effects.
The scientific value of excipients can create new chemical and physical interactions appears when evidence is tied to a defined regulatory decision. Buffers, surfactants, preservatives, polymers, colours and flavours can change pH, moisture, oxygen exposure, solubility or degradation. Compatibility and stress studies help distinguish active-ingredient pathways from formulation effects. Keep this boundary visible: Reduced data at submission do not mean reduced responsibility for ongoing real-time studies.
Try this
Build an evidence map for excipients can create new chemical and physical interactions. Trace excipients can create new chemical and physical interactions through manufacture, storage, opening and patient use. Add the decision, owner and acceptance criterion. Keep this limit: Reduced data at submission do not mean reduced responsibility for ongoing real-time studies.
A strong science note separates observation from interpretation. Trace excipients can create new chemical and physical interactions through manufacture, storage, opening and patient use. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace excipients can create new chemical and physical interactions through manufacture, storage, opening and patient use. Keep this boundary visible: Reduced data at submission do not mean reduced responsibility for ongoing real-time studies.
CHAPTER 8 OF 17 · Carry knowledge forward
8. Manufacturing history affects the starting state
Granulation, sterilisation, milling, mixing, drying, filling or coating can alter crystal form, impurity profile, particle size or water content. Representative stability batches should begin with material made by a process that reflects the intended commercial product.
For manufacturing history affects the starting state, a useful explanation shows the material, method, result and decision together. Granulation, sterilisation, milling, mixing, drying, filling or coating can alter crystal form, impurity profile, particle size or water content. Representative stability batches should begin with material made by a process that reflects the intended commercial product. Preserve this guardrail: The June 2025 consolidated Q1 document remains a draft, not for implementation.
Try this
Challenge the assumptions behind manufacturing history affects the starting state. Reassess manufacturing history affects the starting state after a formulation, site, process, strength or package change. Test a plausible failure mode and record the result. Respect this boundary: The June 2025 consolidated Q1 document remains a draft, not for implementation.
A strong science note separates observation from interpretation. Reassess manufacturing history affects the starting state after a formulation, site, process, strength or package change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reassess manufacturing history affects the starting state after a formulation, site, process, strength or package change. Keep this boundary visible: The June 2025 consolidated Q1 document remains a draft, not for implementation.
CHAPTER 9 OF 17 · Test what changed
9. The proposed package belongs to the dosage form
A liquid in a permeable bottle, a sterile solution in a vial, a unit-dose blister or a multidose device experiences different moisture, oxygen, light and microbial risks. The marketed container closure and orientation are part of the stability claim.
A trustworthy account of the proposed package belongs to the dosage form keeps assumptions, uncertainty and lifecycle action in the same record. A liquid in a permeable bottle, a sterile solution in a vial, a unit-dose blister or a multidose device experiences different moisture, oxygen, light and microbial risks. The marketed container closure and orientation are part of the stability claim. Remember: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
Try this
Audit the lifecycle record for the proposed package belongs to the dosage form. Compare the proposed package belongs to the dosage form with the approved product and list every new uncertainty. Mark what changed, why it changed and what evidence closed the question. Preserve this caution: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
A strong science note separates observation from interpretation. Compare the proposed package belongs to the dosage form with the approved product and list every new uncertainty. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Compare the proposed package belongs to the dosage form with the approved product and list every new uncertainty. Keep this boundary visible: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
CHAPTER 10 OF 17 · Test what changed
10. Q1A-style long-term and accelerated studies remain the foundation
Conditions, batch representation, testing frequency, analytical procedures and acceptance criteria follow the parent principles. Product knowledge can shape the design, but a new dosage form does not receive an unexplained exemption from real-time evidence.
The scientific value of q1a-style long-term and accelerated studies remain the foundation appears when evidence is tied to a defined regulatory decision. Conditions, batch representation, testing frequency, analytical procedures and acceptance criteria follow the parent principles. Product knowledge can shape the design, but a new dosage form does not receive an unexplained exemption from real-time evidence. Keep this boundary visible: A new route or delivery system can create patient-relevant attributes absent from the original dosage form.
Try this
Build an evidence map for q1a-style long-term and accelerated studies remain the foundation. Stress the formulation and package assumptions behind q1a-style long-term and accelerated studies remain the foundation. Add the decision, owner and acceptance criterion. Keep this limit: A new route or delivery system can create patient-relevant attributes absent from the original dosage form.
A strong science note separates observation from interpretation. Stress the formulation and package assumptions behind q1a-style long-term and accelerated studies remain the foundation. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Stress the formulation and package assumptions behind q1a-style long-term and accelerated studies remain the foundation. Keep this boundary visible: A new route or delivery system can create patient-relevant attributes absent from the original dosage form.
CHAPTER 11 OF 17 · Test what changed
11. Attributes follow the new product’s quality risks
Assay and degradation products may be joined by dissolution, delivery rate, resuspendability, viscosity, pH, water, appearance, sterility, microbial limits or preservative content. Tests are selected because they protect product performance and patients.
For attributes follow the new product’s quality risks, a useful explanation shows the material, method, result and decision together. Assay and degradation products may be joined by dissolution, delivery rate, resuspendability, viscosity, pH, water, appearance, sterility, microbial limits or preservative content. Tests are selected because they protect product performance and patients. Preserve this guardrail: Reduced data at submission do not mean reduced responsibility for ongoing real-time studies.
Try this
Challenge the assumptions behind attributes follow the new product’s quality risks. Trace attributes follow the new product’s quality risks through manufacture, storage, opening and patient use. Test a plausible failure mode and record the result. Respect this boundary: Reduced data at submission do not mean reduced responsibility for ongoing real-time studies.
A strong science note separates observation from interpretation. Trace attributes follow the new product’s quality risks through manufacture, storage, opening and patient use. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace attributes follow the new product’s quality risks through manufacture, storage, opening and patient use. Keep this boundary visible: Reduced data at submission do not mean reduced responsibility for ongoing real-time studies.
CHAPTER 12 OF 17 · Test what changed
12. Stability-indicating methods must work in the new matrix
An analytical procedure validated for an old tablet may experience interference in a flavoured liquid or polymeric patch. Specificity, recovery, sample preparation and detection of relevant change are demonstrated for the actual dosage form.
A trustworthy account of stability-indicating methods must work in the new matrix keeps assumptions, uncertainty and lifecycle action in the same record. An analytical procedure validated for an old tablet may experience interference in a flavoured liquid or polymeric patch. Specificity, recovery, sample preparation and detection of relevant change are demonstrated for the actual dosage form. Remember: The June 2025 consolidated Q1 document remains a draft, not for implementation.
Try this
Audit the lifecycle record for stability-indicating methods must work in the new matrix. Reassess stability-indicating methods must work in the new matrix after a formulation, site, process, strength or package change. Mark what changed, why it changed and what evidence closed the question. Preserve this caution: The June 2025 consolidated Q1 document remains a draft, not for implementation.
A strong science note separates observation from interpretation. Reassess stability-indicating methods must work in the new matrix after a formulation, site, process, strength or package change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reassess stability-indicating methods must work in the new matrix after a formulation, site, process, strength or package change. Keep this boundary visible: The June 2025 consolidated Q1 document remains a draft, not for implementation.
CHAPTER 13 OF 17 · Support the shelf life
13. Comparative data can make the bridge transparent
Side-by-side stress, degradation, impurity or physical-behaviour information can show what knowledge transfers and where the new form diverges. A bridge is strongest when it states both similarities and new uncertainties.
The scientific value of comparative data can make the bridge transparent appears when evidence is tied to a defined regulatory decision. Side-by-side stress, degradation, impurity or physical-behaviour information can show what knowledge transfers and where the new form diverges. A bridge is strongest when it states both similarities and new uncertainties. Keep this boundary visible: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
Try this
Build an evidence map for comparative data can make the bridge transparent. Compare comparative data can make the bridge transparent with the approved product and list every new uncertainty. Add the decision, owner and acceptance criterion. Keep this limit: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
A strong science note separates observation from interpretation. Compare comparative data can make the bridge transparent with the approved product and list every new uncertainty. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Compare comparative data can make the bridge transparent with the approved product and list every new uncertainty. Keep this boundary visible: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
CHAPTER 14 OF 17 · Support the shelf life
14. Reduced submission data require justification and commitments
Q1C notes that a reduced stability database may be acceptable in some circumstances. The amount depends on available knowledge and regional expectations. Ongoing studies on production batches complete the evidence and can challenge the initial shelf-life proposal.
For reduced submission data require justification and commitments, a useful explanation shows the material, method, result and decision together. Q1C notes that a reduced stability database may be acceptable in some circumstances. The amount depends on available knowledge and regional expectations. Ongoing studies on production batches complete the evidence and can challenge the initial shelf-life proposal. Preserve this guardrail: A new route or delivery system can create patient-relevant attributes absent from the original dosage form.
Try this
Challenge the assumptions behind reduced submission data require justification and commitments. Stress the formulation and package assumptions behind reduced submission data require justification and commitments. Test a plausible failure mode and record the result. Respect this boundary: A new route or delivery system can create patient-relevant attributes absent from the original dosage form.
A strong science note separates observation from interpretation. Stress the formulation and package assumptions behind reduced submission data require justification and commitments. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Stress the formulation and package assumptions behind reduced submission data require justification and commitments. Keep this boundary visible: A new route or delivery system can create patient-relevant attributes absent from the original dosage form.
CHAPTER 15 OF 17 · Support the shelf life
15. In-use stability may matter after opening or preparation
Reconstitution, dilution, repeated container entry, device loading or removal from protective packaging can create a second clock. The study simulates actual handling and supports clear instructions for patients and health professionals.
A trustworthy account of in-use stability may matter after opening or preparation keeps assumptions, uncertainty and lifecycle action in the same record. Reconstitution, dilution, repeated container entry, device loading or removal from protective packaging can create a second clock. The study simulates actual handling and supports clear instructions for patients and health professionals. Remember: Reduced data at submission do not mean reduced responsibility for ongoing real-time studies.
Try this
Audit the lifecycle record for in-use stability may matter after opening or preparation. Trace in-use stability may matter after opening or preparation through manufacture, storage, opening and patient use. Mark what changed, why it changed and what evidence closed the question. Preserve this caution: Reduced data at submission do not mean reduced responsibility for ongoing real-time studies.
A strong science note separates observation from interpretation. Trace in-use stability may matter after opening or preparation through manufacture, storage, opening and patient use. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace in-use stability may matter after opening or preparation through manufacture, storage, opening and patient use. Keep this boundary visible: Reduced data at submission do not mean reduced responsibility for ongoing real-time studies.
CHAPTER 16 OF 17 · Support the shelf life
16. Lifecycle changes can reopen the stability bridge
A new excipient supplier, process, strength, site, closure or device component can change the original risk balance. Change management determines whether prior Q1C evidence still applies and what comparability or stability data are needed.
The scientific value of lifecycle changes can reopen the stability bridge appears when evidence is tied to a defined regulatory decision. A new excipient supplier, process, strength, site, closure or device component can change the original risk balance. Change management determines whether prior Q1C evidence still applies and what comparability or stability data are needed. Keep this boundary visible: The June 2025 consolidated Q1 document remains a draft, not for implementation.
Try this
Build an evidence map for lifecycle changes can reopen the stability bridge. Reassess lifecycle changes can reopen the stability bridge after a formulation, site, process, strength or package change. Add the decision, owner and acceptance criterion. Keep this limit: The June 2025 consolidated Q1 document remains a draft, not for implementation.
A strong science note separates observation from interpretation. Reassess lifecycle changes can reopen the stability bridge after a formulation, site, process, strength or package change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reassess lifecycle changes can reopen the stability bridge after a formulation, site, process, strength or package change. Keep this boundary visible: The June 2025 consolidated Q1 document remains a draft, not for implementation.
CHAPTER 17 OF 17 · Support the shelf life
17. A complete Q1C receipt explains why the new form remains suitable
The record includes approved-product knowledge, dosage-form differences, route, formulation, process, strengths, package, risk assessment, batches, conditions, methods, attributes, specifications, results, bridge rationale, in-use studies, proposed shelf life and continuing commitments.
For a complete q1c receipt explains why the new form remains suitable, a useful explanation shows the material, method, result and decision together. The record includes approved-product knowledge, dosage-form differences, route, formulation, process, strengths, package, risk assessment, batches, conditions, methods, attributes, specifications, results, bridge rationale, in-use studies, proposed shelf life and continuing commitments. Preserve this guardrail: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
Try this
Challenge the assumptions behind a complete q1c receipt explains why the new form remains suitable. Compare a complete q1c receipt explains why the new form remains suitable with the approved product and list every new uncertainty. Test a plausible failure mode and record the result. Respect this boundary: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
A strong science note separates observation from interpretation. Compare a complete q1c receipt explains why the new form remains suitable with the approved product and list every new uncertainty. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Compare a complete q1c receipt explains why the new form remains suitable with the approved product and list every new uncertainty. Keep this boundary visible: Prior stability knowledge belongs to the earlier product and transfers only through a justified scientific bridge.
Q1C new-dosage-form map
| Question | Evidence to capture | Boundary to retain |
|---|---|---|
| What remains known? | Active ingredient and approved-product history | Use prior knowledge carefully |
| What changed? | Dosage form, route, excipients, process and package | Name every new risk |
| What must be tested? | Chemical, physical, biological and microbiological attributes | Use fit-for-form methods |
| What supports the claim? | Long-term data, bridge and commitments | Maintain lifecycle evidence |
Science learning becomes useful when a student can show where a claim came from, why it applies and where it stops. Continue with the eduKate Science Learning Hub, compare choices in the Education Hub, and connect these habits to career pathways built from subject capabilities.
Q1C is optimistic science: an established medicine can become easier to take, safer to deliver or better suited to a patient population. That innovation remains trustworthy when the old knowledge is carried forward honestly and every new formulation, package and use risk receives fresh evidence.
Primary sources and verification date
Source status checked 26 October 2026. FDA guidance describes the agency’s current thinking and does not replace applicable statutes, regulations or product-specific communication with FDA.
- FDA: Q1C Stability Testing for New Dosage Forms — Final guidance, May 1997.
- FDA: Q1A(R2) Stability Testing — Final parent guidance, November 2003.
- FDA: Consolidated ICH Q1 stability draft — Draft guidance, June 2025; not for implementation.